<DOC>
	<DOCNO>NCT01020578</DOCNO>
	<brief_summary>Impaired glucose tolerance associate increase risk develop cardiovascular disease atherosclerosis reason yet totally understood . Previous study evaluate kinetics plasma LDL faster removal rate free cholesterol normolipidemic patient diagnose arterial coronary disease deposit cholesterol blood vessel wall . This disassociation cholesterol may suggest new mechanism genesis progression arterial coronary disease . The objective research study plasma kinetics free cholesterol cholesterol ester impair glucose tolerance patient , asymptomatic coronary artery disease ( CAD ) , elucidate mechanism involve atherogenesis patient .</brief_summary>
	<brief_title>Low Density Lipoprotein ( LDL ) Cholesterol Metabolism Impaired Glucose Tolerance</brief_title>
	<detailed_description>Along hyperglycemia , presence obesity dyslipidemia , risk factor associate natural onset diabetes mellitus type 2 , could possibly explain high susceptibility glucose intolerance cardiovascular disease . Dyslipidemia commonly link glucose intolerance characterize hypertriglyceridemia , low HDL-C spite LDL-C apparently normal slightly elevate , presence small dense LDL . Formulated laboratory , artificial lipid nanoemulsion mark 14C-cholesterol ester 3H-cholesterol lipid composition similar LDL allow study plasma kinetics two form cholesterol ( free esterify . The nanoemulsion mimic natural LDL , prepare without protein . In contact bloodstream , nanoemulsion acquires apolipoproteins , apo E preferentially , allow recognize remove plasma LDL receptor . The application nanoemulsion show technically safe , appropriate simple use human order understand role dyslipidemia atherogenic process .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>total cholesterol &lt; 6mmol/L LDLC &lt; 4mmol/L triacylglycerides &lt; 2.2mmol/L normal blood pressure hypertension 130/85 mmHg presence previous cardiovascular disease : macrovascular , peripheral arterial disease cerebral stroke . presence chronic disease : chronic renal failure ( creatinin &gt; 30 ug/mg ) , hepatic failure , asthma , chronic obstructive pulmonary disease , inflammatory disease , oncology thyropathy compensate . use drug : statin , fibrates , glucocorticoid metformin</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>